Ireland· IE-PA-EU/1/12/807/9,12,13,15
Tresiba 200 units/mL solution for injection in pre-filled pen
A insulin degludec product containing insulin degludec (ideg), registered in Ireland by Novo Nordisk A/S. The same ATC class is registered in 14 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Insulin degludec is registered in 14 of 19 countries.
Countries holding a registration under ATC A10AE06 (insulin degludec), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 9 of them publish a price we can compare per daily dose
Insulin degludec · ATC A10AE06
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
HPRA (Ireland)- Active substance
- Insulin degludec (ideg)
- Manufacturer
- Novo Nordisk A/S
- Country
- Ireland (IE)
- ATC code
- A10AE06
- ATC class
- Insulin degludec
- Defined daily dose
- 40 E, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/12/807/9,12,13,15
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
431 interactions on record for insulin degludec.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Insulin degludec · interactions on record
431 records
- 15 severe
- 366 moderate
- 50 minor
Most severe, free to view
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- PrednisoloneA07EA01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Insulin degludec in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaTRESIBANovo Nordisk A/S, Bagsvaerd
- United StatesInsulin DegludecNovo Nordisk Pharma, Inc.
- BelgiumRyzodeg 100 U/mlNovo Nordisk
- United KingdomTresiba FlexTouch 100units/ml solution for injection 3ml pre-filled pensNovo Nordisk Ltd
- FinlandTresibaOrifarm Oy
- SpainTRESIBA 100 UNIDADES/ML FLEXTOUCH SOLUCION INYECTABLE EN PLUMA PRECARGADANovo Nordisk A/S
- SwedenTresiba FlexPen 100 enheter/ml Injektionsvätska, lösning i förfylld injektionspennaNovo Nordisk A/S
- SwitzerlandTresiba FlexTouch 100 E/ml, InjektionslösungNovo Nordisk Pharma AG
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Tresiba Flexpen, Tresiba Flextouch
- Norway · Tresiba, Tresiba Flexpen
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b9646f5d-7c56-4ec4-afaf-f29b1b3790ff GET /v1/drugs/b9646f5d-7c56-4ec4-afaf-f29b1b3790ff?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection in pre-filled pen",
"routes": [
"Subcutaneous use"
],
"source": "hpra",
"atc_all": [
"A10AE",
"A10AE06"
],
"strength": null,
"pa_number": "EU/1/12/807/9,12,13,15",
"substances": [
"Insulin degludec (ideg)"
],
"legal_basis": "New active substance (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": null,
"dispensing_status": "Product subject to prescription which may be renewed (B)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about insulin degludec.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.